100+ total transactions representing $5B+ in aggregate value — 10 tracked below spanning 2017–2024 · 1 industry
RM Global Partners served as strategic advisor on merger of EPD Biotherapeutics with Genexine to strengthen drug development pipeline. Genexine is a publicly traded Korean biotech firm.
RM Global Partners served as advisor to GC Biopharma on acquisition of rare disease pipeline in hematology from Catalyst Biosciences. Expands GC Biopharma's clinical pipeline in rare blood disorders.
RM Global Partners served as advisor to Chong Kun Dang Pharma on global licensing agreement for Synaffix ADC (antibody-drug conjugate) technology. Adds novel oncology candidate to CKD pipeline.
RM Global Partners served as advisor on licensing agreement for DYRK1A inhibitor platform. Technology has potential in rare genetic disorders and other rare diseases.
RM Global Partners participated as investor in Series B financing round for ImmPACT Bio, a clinical-stage immunotherapy company developing novel B-cell therapies for hematologic malignancies.
RM Global Partners served as strategic advisor on divestiture and spin-off of TETEC-AESCULAP global orthobiologics business to Octane Medical. Demonstrates expertise in complex divestitures and spin-outs.
RM Global Partners served as advisor on Series C financing for Nectero Medical, a biotech company developing therapeutic technologies.
RM Global Partners served as advisor on Series A financing for R3 Vascular, a medical device company developing innovative vascular intervention solutions.
RM Global Partners (RMGP BioPharma Investment Fund) participated as significant investor in BiomX merger with Chardan Healthcare Acquisition Corp. BiomX is an Israeli microbiome-focused therapeutic company. Transaction brought Israeli biotech innovation to US public markets.
RM Global Partners (co-founders Yaron Breski, Assaf Keret, Ted Moon, Bruce Roberts) completed first closing of $30M RMGP BioPharma Fund in partnership with FutuRx (Israel-based drug development platform backed by OrbiMed, Johnson & Johnson, Takeda). Fund invests in early-stage innovative biopharmaceutical assets.